OA12099A - 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. - Google Patents
4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. Download PDFInfo
- Publication number
- OA12099A OA12099A OA1200200158A OA1200200158A OA12099A OA 12099 A OA12099 A OA 12099A OA 1200200158 A OA1200200158 A OA 1200200158A OA 1200200158 A OA1200200158 A OA 1200200158A OA 12099 A OA12099 A OA 12099A
- Authority
- OA
- OAPI
- Prior art keywords
- crystal
- trifluoromethyl
- formula
- quinoline
- carboxylic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16805199P | 1999-11-30 | 1999-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA12099A true OA12099A (en) | 2006-05-04 |
Family
ID=22609901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200200158A OA12099A (en) | 1999-11-30 | 2000-11-14 | 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1246804A1 (ru) |
JP (1) | JP2003515592A (ru) |
KR (1) | KR20020058057A (ru) |
CN (1) | CN1402711A (ru) |
AP (1) | AP2002002531A0 (ru) |
AU (1) | AU1048801A (ru) |
BG (1) | BG106854A (ru) |
BR (1) | BR0015836A (ru) |
CA (1) | CA2392979A1 (ru) |
CO (1) | CO5271716A1 (ru) |
EA (1) | EA200200510A1 (ru) |
EC (1) | ECSP003792A (ru) |
EE (1) | EE200200277A (ru) |
GT (1) | GT200000199A (ru) |
HU (1) | HUP0203521A2 (ru) |
IL (1) | IL149097A0 (ru) |
IS (1) | IS6338A (ru) |
MA (1) | MA26845A1 (ru) |
MX (1) | MXPA02005354A (ru) |
NO (1) | NO20022558L (ru) |
OA (1) | OA12099A (ru) |
PA (1) | PA8506301A1 (ru) |
PE (1) | PE20010904A1 (ru) |
PL (1) | PL355892A1 (ru) |
TN (1) | TNSN00231A1 (ru) |
TR (1) | TR200201446T2 (ru) |
UY (1) | UY26454A1 (ru) |
WO (1) | WO2001040190A1 (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
IL158765A0 (en) | 2001-06-21 | 2004-05-12 | Pfizer Prod Inc | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
GT200200170A (es) * | 2001-09-28 | 2003-05-23 | Preparacion de inhibidor de cetp anhidro | |
EP1920766B1 (en) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
CN1309370C (zh) * | 2002-02-01 | 2007-04-11 | 辉瑞产品公司 | 使用改进的喷雾干燥设备制备均匀喷雾干燥的固体非晶形药物分散体的方法 |
ES2305434T3 (es) | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
SI1533292T1 (sl) | 2002-08-30 | 2007-08-31 | Japan Tobacco Inc | Dibenzilaminska spojina in njena medicinska uporaba |
PL376156A1 (en) | 2002-10-04 | 2005-12-27 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
JP2006513186A (ja) | 2002-12-20 | 2006-04-20 | ファイザー・プロダクツ・インク | Cetp阻害剤およびhmg−coaレダクターゼ阻害剤を含む剤形 |
BRPI0408897A (pt) * | 2003-03-28 | 2006-04-18 | Pfizer Prod Inc | derivados de 1,2,3,4-tetrahidro-e 1,2-dihidro-quinolina 1,2,4-substituìdos como inibidores de cetp para o tratamento de arteroesclerose e obesidade |
MXPA06001417A (es) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas. |
DK1670768T3 (da) | 2003-10-08 | 2009-11-09 | Lilly Co Eli | Forbindelser og fremgangsmåder til at behandle dyslipidæmi |
EP1737811B1 (en) * | 2004-04-13 | 2016-08-10 | Merck Sharp & Dohme Corp. | Cetp inhibitors |
JP2008504266A (ja) * | 2004-06-24 | 2008-02-14 | イーライ リリー アンド カンパニー | 異脂肪血症を治療するための化合物及び方法 |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
WO2006033004A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds as cetp inhibitors |
UA90706C2 (ru) | 2005-02-24 | 2010-05-25 | Милленниум Фармасьютикалз, Инк. | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний |
WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
AR065670A1 (es) | 2007-03-09 | 2009-06-24 | Indigene Pharmaceuticals Inc | Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
TWI450896B (zh) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸 |
MX2017000582A (es) | 2014-07-30 | 2017-04-27 | Hoffmann La Roche | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
WO1998033775A1 (en) * | 1997-02-03 | 1998-08-06 | American Home Products Corporation | 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/es unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/es unknown
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/xx unknown
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/pt not_active IP Right Cessation
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/ko not_active Application Discontinuation
- 2000-11-14 EE EEP200200277A patent/EE200200277A/xx unknown
- 2000-11-14 IL IL14909700A patent/IL149097A0/xx unknown
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/es unknown
- 2000-11-14 PL PL00355892A patent/PL355892A1/xx not_active Application Discontinuation
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 CN CN00816463A patent/CN1402711A/zh active Pending
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/en not_active Application Discontinuation
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/hu unknown
- 2000-11-14 EP EP00971662A patent/EP1246804A1/en not_active Withdrawn
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 EA EA200200510A patent/EA200200510A1/ru unknown
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/ja active Pending
- 2000-11-14 CA CA002392979A patent/CA2392979A1/en not_active Abandoned
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-28 UY UY26454A patent/UY26454A1/es not_active Application Discontinuation
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/es not_active Application Discontinuation
- 2000-11-29 GT GT200000199A patent/GT200000199A/es unknown
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/es unknown
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/fr unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/is unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/fr unknown
- 2002-05-29 NO NO20022558A patent/NO20022558L/no not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
TNSN00231A1 (fr) | 2002-05-30 |
JP2003515592A (ja) | 2003-05-07 |
IL149097A0 (en) | 2002-11-10 |
EA200200510A1 (ru) | 2002-10-31 |
EE200200277A (et) | 2003-10-15 |
CO5271716A1 (es) | 2003-04-30 |
EP1246804A1 (en) | 2002-10-09 |
PE20010904A1 (es) | 2001-09-10 |
ECSP003792A (es) | 2002-04-23 |
KR20020058057A (ko) | 2002-07-12 |
BG106854A (bg) | 2002-12-29 |
WO2001040190A1 (en) | 2001-06-07 |
AU1048801A (en) | 2001-06-12 |
IS6338A (is) | 2002-04-12 |
NO20022558D0 (no) | 2002-05-29 |
CN1402711A (zh) | 2003-03-12 |
MA26845A1 (fr) | 2004-12-20 |
PA8506301A1 (es) | 2002-08-26 |
UY26454A1 (es) | 2001-07-31 |
CA2392979A1 (en) | 2001-06-07 |
PL355892A1 (en) | 2004-05-31 |
BR0015836A (pt) | 2002-08-06 |
GT200000199A (es) | 2002-05-23 |
TR200201446T2 (tr) | 2002-11-21 |
AP2002002531A0 (en) | 2002-06-30 |
NO20022558L (no) | 2002-05-29 |
HUP0203521A2 (hu) | 2003-02-28 |
MXPA02005354A (es) | 2002-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA12099A (en) | 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinolinecrystal as CETP inhibitor. | |
US6313142B1 (en) | Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline | |
TWI685486B (zh) | 製備pde4抑制劑之方法 | |
AU2002358585A1 (en) | Acetylene derivatives having mglur 5 antagonistic activity | |
ZA200600156B (en) | Tacrine derivatives as inhibitors of acetylcholinesterase | |
EP3863755A1 (en) | Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators | |
PT87277B (pt) | Processo para a preparacao de novos compostos biciclicos e composicoes farmaceuticas compreendendo os mesmos | |
IE43736B1 (en) | 3-aminomethylene-6 7-dimethoxy-2-methyl-4-oxo-1,2,3,4-tetrahydro-1-quinoline carboxylic acid esters | |
US6063784A (en) | Heteroaryloxyethylamines, method of preparation, application as medicine and pharmaceutical compositions containing them | |
JPH03218361A (ja) | 9―アシルアミノテトラヒドロアクリジン誘導体 | |
CA2090635A1 (en) | Substituted phenylquinazoline derivatives | |
MXPA00011855A (en) | Method for making (-)-(2r,4s)-4- [(3,5-bis- trifluoromethyl-benzyl)- methoxycarbonylamino]- 2-ethyl-6- trifluoromethyl-3,4-dihydro- 2h-quinoline- 1-carboxylic acid ethyl ester | |
GB2098205A (en) | Indoles | |
WO1997005114A1 (en) | Quinolone sulfonimides having leukotriene-antagonistic action | |
BE550426A (ru) |